ascopubs.org

A phase 0/1 trigger trial of BDTX-1535 in patients with recurrent high-grade glioma (HGG) with EGFR alterations or fusions.

Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results. This is an ASCO Meeting Abstract from the 2024 ...
ascopubs.org

A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) nanoconjugate targeting BCL2L12 in recurrent glioblastoma patients.

Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status. This is an ASCO ...
Nature

Phase 0 trials for anticancer drug development

The results of the first 'Phase 0' clinical trial in oncology of a therapeutic agent under the Exploratory Investigational New Drug Guidance of the US FDA have ...
FierceBiotech

Presage inks its 3rd deal around phase 0 studies—with more to come

Nearly four months after teaming up with Celgene, Presage Biosciences has snagged another major cancer player as a partner: Bristol-Myers Squibb. The Big Pharma will use Presage’s microdosing ...